Fig. 4From: Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugsImpact of PAVD use on iVDPV prevalence for different PAVD use scenarios starting on January 1, 2020, based on the first 100 stochastic iterations of the DES model. a Lower bound on effectiveness of a single PAVD compound (i.e., assuming 40Â % of recipients recover from infection). b Hypothetical upper bound on effectiveness of one or more PAVD compounds (i.e., assuming 90Â % of recipients recover from infection)Back to article page